AbbVie Inc. v. Aurobindo Pharma Limited
1:17-cv-00047
Overview
Parties
Defendant
Aurobindo Pharma Limited NPE (University / Research)
Represented By
1 Attorneys ListedConnolly Gallagher LLP
1201 North Market Street, 20th Floor, Wilmington, DE 19801
Aurobindo Pharma USA, Inc. Operating Company
Represented By
1 Attorneys ListedConnolly Gallagher LLP
1201 North Market Street, 20th Floor, Wilmington, DE 19801
AbbVie Inc. Operating Company
Represented By
2 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Plaintiff
Abbvie Deutschland GMBH & Co. KG Operating Company
Represented By
2 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 5 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | US 7,148,359 B2 Asserted | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 9,343,298 P | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 13,753,599 P | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 6,894,171 B1 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 7,183,416 B2 | US Continuation / Sibling | View Official Patent → |
AbbVie Inc. v. Amneal Pharmaceuticals, LLC
AbbVie Inc. v. Mylan Pharmaceuticals Inc.
AbbVie Inc. v. Hetero Labs Limited
AbbVie Inc. v. Aurobindo Pharma Limited
AbbVie Inc. v. Roxane Laboratories Inc.
AbbVie Inc. v. Mylan Pharmaceuticals Inc.
AbbVie Inc. v. Roxane Laboratories Inc.
Patents Involved
There are 9 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US7148359
Polymorph of a pharmaceutical
|
Filed: 2005-05-04
Issued: 2006-12-12
|
Expired (Term Ended)
Expires: 2025-05-04
|
|
|
US7364752
Solid dispersion pharamaceutical formulations
|
Filed: 2000-11-10
Issued: 2008-04-29
|
Expired (Term Ended)
+688d PTA
Expires: 2022-09-29
|
|
|
US8025899
Solid pharmaceutical dosage form
|
Filed: 2004-08-25
Issued: 2011-09-27
|
Active (1.1 yrs remaining)
+1206d PTA
Expires: 2027-12-14
|
|
|
US8268349
Solid pharmaceutical dosage form
|
Filed: 2012-04-18
Issued: 2012-09-18
|
Active (5.4 yrs remaining)
Expires: 2032-04-18
|
|
|
US8309613
Solid pharmaceutical dosage form
|
Filed: 2010-09-13
Issued: 2012-11-13
|
Expired (Term Ended)
Expires: 2024-12-24
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred β Patent expired. Under 35 U.S.C. Β§ 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.
Standard Statutory Term β No obviousness-type double patenting truncation noted.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).